Compare NTLA & ETG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | ETG |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2016 | 2003 |
| Metric | NTLA | ETG |
|---|---|---|
| Price | $13.78 | $21.12 |
| Analyst Decision | Buy | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $20.45 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 145.8K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $62.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $6.67 | $16.87 |
| 52 Week High | $28.24 | $23.67 |
| Indicator | NTLA | ETG |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 52.17 |
| Support Level | $11.63 | $21.05 |
| Resistance Level | $14.32 | $22.27 |
| Average True Range (ATR) | 0.76 | 0.46 |
| MACD | 0.09 | 0.19 |
| Stochastic Oscillator | 76.31 | 88.30 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Eaton Vance Tax Advgd Gbl Div Inc Fd is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of aerospace and defense, capital markets, diversified telecommunication services, electrical equipment, biotechnology, banks, and other areas.